Preventing and Treating Anthracycline Cardiotoxicity: New Insights.
Annu Rev Pharmacol Toxicol
; 61: 309-332, 2021 01 06.
Article
en En
| MEDLINE
| ID: mdl-33022184
ABSTRACT
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Antraciclinas
/
Neoplasias
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Annu Rev Pharmacol Toxicol
Año:
2021
Tipo del documento:
Article